C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025)
C4 Therapeutics (CCCC) posted quarterly Non Operating Investment Income of -$73000.0 for Q2 2025, down 21.67% year-over-year from -$93191.5 in Q2 2024, and down 630.0% quarter-over-quarter from -$10000.0 in Q1 2025.
Powered by 
Analysis
C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025) Analysis & Trends
C4 Therapeutics' Non Operating Investment Income history runs 6 years deep, the most recent figure standing at -$73000.0 for Q2 2025.
- In Q2 2025, Non Operating Investment Income fell 21.67% year-over-year to -$73000.0; the TTM figure through Jun 2025 stood at $410000.0 (down 69.27% YoY), while the FY2025 annual figure was -$3000.0, down 101.67% from the prior year.
- Non Operating Investment Income for Q2 2025 stood at -$73000.0, down from -$10000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $1.7 million in Q1 2023, with the low at -$2.9 million in Q1 2022.
- The 5-year median for Non Operating Investment Income is -$66500.0 (2024), against an average of -$2388.9.
- Peak annual rise in Non Operating Investment Income reached 1350.0% in 2021, while the deepest fall reached 12500.0% in 2021.
- C4 Therapeutics' Non Operating Investment Income stood at -$620000.0 in 2021, then jumped by 305.16% to $1.3 million in 2022, then slumped by 38.92% to $777000.0 in 2023, then sank by 151.74% to -$402000.0 in 2024, then surged by 81.84% to -$73000.0 in 2025.
- Business Quant data shows CCCC's Non Operating Investment Income at -$73000.0 in Q2 2025, -$10000.0 in Q1 2025, and -$402000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | C4 Therapeutics | 492.73 Mn | 239.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | -402,000.00 |
| Sep 30, 2024 | 895,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -253,000.00 |
| Dec 31, 2023 | 777,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Jun 30, 2023 | 696,000.00 |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | -828,000.00 |
| Jun 30, 2022 | -931,000.00 |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -620,000.00 |
| Sep 30, 2021 | -86,000.00 |
| Jun 30, 2021 | 25,000.00 |
| Mar 31, 2021 | -107,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 10,000.00 |